FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Schiller

Research Profile

Living Beings

Disorders

Chemicals & Drugs

Anatomy

Procedures

Physiology

Transfection

Co-author Network

Publications

TOP 3
Subhashini Jagu; Kirill Kalnin; Harold Kleanthous; Kihyuck Kwak; Douglas R Lowy; Sudha V Chivukula; Louise T Chow; Warner K Huh; Kilvani S Jaganathan; John T Schiller; Chenguang Wang; Hsu-kun Wang; Richard B S Roden
Phylogenetic considerations in designing a broadly protective multimeric l2 vaccine.
Patricia M Day; Douglas Lowy; Rachel M Schowalter; Cynthia D Thompson; John T Schiller
Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection.
S Domingos-Pereira; P Jichlinski; Martine Bobst; L Decrausaz; L Derré; P Romero; John T Schiller; Denise Nardelli-Haefliger
Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Schiller (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Subhashini Jagu; Kirill Kalnin; Harold Kleanthous; Kihyuck Kwak; Douglas R Lowy; Sudha V Chivukula; Louise T Chow; Warner K Huh; Kilvani S Jaganathan; John T Schiller; Chenguang Wang; Hsu-kun Wang; Richard B S Roden
Phylogenetic considerations in designing a broadly protective multimeric l2 vaccine.
Journal of virology 2013;87(11):6127-36.
2013: Patricia M Day; Douglas Lowy; Rachel M Schowalter; Cynthia D Thompson; John T Schiller
Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection.
Journal of virology 2013;87(7):3862-70.
2013: S Domingos-Pereira; P Jichlinski; Martine Bobst; L Decrausaz; L Derré; P Romero; John T Schiller; Denise Nardelli-Haefliger
Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice.
Mucosal immunology 2013;6(2):393-404.
2012: Troy J Kemp; Douglas R Lowy; Yuanji Pan; Kerri J Penrose; Rolando Herrero; Allan Hildesheim; Carolina Porras; Mahboobeh Safaeian; John T Schiller; Ligia A Pinto
Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®).
Vaccine 2012;31(1):165-70.
2012: Nicolas Cuburu; Christopher B Buck; Patricia M Day; Barney S Graham; Rhonda C Kines; Douglas R Lowy; Yuk-Ying S Pang; John T Schiller
Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.
The Journal of clinical investigation 2012;122(12):4606-20.
2012: Alessandra Handisurya; Kihyuck Kwak; Douglas R Lowy; Richard B S Roden; Christopher B Buck; Patricia M Day; Cynthia D Thompson; John T Schiller
Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species.
Virology 2012;433(2):385-94.
2012: John T Schiller; Xavier Castellsagué; Suzanne M Garland
A review of clinical trials of human papillomavirus prophylactic vaccines.
Vaccine 2012;30 Suppl 5():F123-38.
2012: John T Schiller; Douglas R Lowy
Understanding and learning from the success of prophylactic human papillomavirus vaccines.
Nature reviews. Microbiology 2012;10(10):681-92.
2012: Patricia M Day; Rhonda C Kines; Douglas R Lowy; Yuk-Ying S Pang; Cynthia D Thompson; John T Schiller
A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.
Clinical and vaccine immunology : CVI 2012;19(7):1075-82.
2011: Stéphanie Longet; Martine Bobst; Patrice Jichlinski; John T Schiller; Denise Nardelli-Haefliger
A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection.
Journal of virology 2011;85(24):13253-9.
2011: Nirujogi Hanumantha Rao; Yuk-Ying S Pang; L Rajendra; John T Schiller; P Baji Babu; Rajan Sriraman; Villuppanoor Alwar Srinivasan
Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.
Vaccine 2011;29(43):7326-34.
2011: Aimée R Kreimer; Douglas Lowy; Carolina Porras; Wim Quint; Ana Cecilia Rodriguez; Mark Schiffman; John T Schiller; John E Schussler; Mark E Sherman; Diane Solomon; Sholom Wacholder; Paula González; Rolando Herrero; Allan Hildesheim; Silvia Jiménez
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.
Journal of the National Cancer Institute 2011;103(19):1444-51.
2011: Rolando Herrero; Allan Hildesheim; Silvia Jiménez; Aimée R Kreimer; Douglas R Lowy; Carolina Porras; Wim Quint; Ana Cecilia Rodríguez; Mark Schiffman; John T Schiller; John E Schussler; Mark E Sherman; Diane Solomon; Sholom Wacholder; Paula González
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica.
Cancer discovery 2011;1(5):408-19.
2011: Aimée R Kreimer; Douglas R Lowy; Carolina Porras; Wim Quint; Ana Cecilia Rodriguez; Mark Schiffman; John T Schiller; Diane Solomon; Linda Struijk; Leen-Jan van Doorn; Sholom Wacholder; Sabrina Chen; Paula González; Rolando Herrero; Allan Hildesheim; Silvia Jiménez; Hormuzd A Katki
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.
The lancet oncology 2011;12(9):862-70.
2011: Loane Decrausaz; Sonia Domingos-Pereira; Mélanie Duc; Patrice Jichlinski; Pedro Romero; John T Schiller; Martine Bobst; Denise Nardelli-Haefliger
Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors.
International journal of cancer. Journal international du cancer 2011;129(3):762-72.
2011: Jeffrey N Roberts; Rhonda C Kines; Hormuzd A Katki; Douglas Lowy; John T Schiller
Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model.
Journal of the National Cancer Institute 2011;103(9):737-43.
2011: Makoto Mitsunaga; Nobuyuki Kosaka; Rhonda C Kines; Jeffrey N Roberts; Douglas Lowy; John T Schiller; Yasushige Ishihara; Akira Hasegawa; Peter L Choyke; Hisataka Kobayashi
In vivo longitudinal imaging of experimental human papillomavirus infection in mice with a multicolor fluorescence mini-endoscopy system.
Cancer prevention research (Philadelphia, Pa.) 2011;4(5):767-73.
2011: Troy J Kemp; Allan Hildesheim; Mahboobeh Safaeian; Joseph G Dauner; Yuanji Pan; Carolina Porras; John T Schiller; Douglas R Lowy; Rolando Herrero; Ligia A Pinto
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.
Vaccine 2011;29(11):2011-4.
2010: Patricia M Day; Rhonda C Kines; Cynthia D Thompson; Subhashini Jagu; Richard B S Roden; Douglas R Lowy; John T Schiller
In vivo mechanisms of vaccine-induced protection against HPV infection.
Cell host & microbe 2010;8(3):260-70.
2010: B S Graham; R C Kines; K S Corbett; J Nicewonger; Teresa Johnson; M Chen; D LaVigne; Jeffrey N Roberts; N Cuburu; John T Schiller; Christopher B Buck
Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.
Mucosal immunology 2010;3(5):475-86.
2010: Jerri do Carmo Caldeira; Alexander Medford; Rhonda C Kines; Christopher A Lino; John T Schiller; Bryce Chackerian; David S Peabody
Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7.
Vaccine 2010;28(27):4384-93.
2010: John T Schiller; Patricia M Day; Rhonda C Kines
Current understanding of the mechanism of HPV infection.
Gynecologic oncology 2010;118(1 Suppl):S12-7.
2010: John T Schiller; Douglas R Lowy
Vaccines to prevent infections by oncoviruses.
Annual review of microbiology 2010;64():23-41.
2009: Nicolas Cuburu; Mi-Na Kweon; Catherine Hervouet; Hye-Ran Cha; Yuk-Ying S Pang; Jan Holmgren; Konrad Stadler; John T Schiller; Fabienne Anjuère; Cecil Czerkinsky
Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection.
Journal of immunology (Baltimore, Md. : 1950) 2009;183(12):7851-9.
2009: Patricia M Day; John T Schiller
The role of furin in papillomavirus infection.
Future microbiology 2009;4(10):1255-62.
2009: Rhonda C Kines; Cynthia D Thompson; Douglas Lowy; John T Schiller; Patricia M Day
The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(48):20458-63.
2009: John T Schiller; Douglas Lowy
Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.
The Journal of infectious diseases 2009;200(2):166-71.
2009: Subhashini Jagu; Balasubramanyam Karanam; Ratish Gambhira; Sudha V Chivukula; Revathi J Chaganti; Douglas Lowy; John T Schiller; Richard B S Roden
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Journal of the National Cancer Institute 2009;101(11):782-92.
2009: Katherine M Johnson; Rhonda C Kines; Jeffrey N Roberts; Douglas Lowy; John T Schiller; Patricia M Day
Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.
Journal of virology 2009;83(5):2067-74.
2008: Patricia M Day; Douglas Lowy; John T Schiller
Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids.
Journal of virology 2008;82(24):12565-8.
2008: Douglas Lowy; Diane Solomon; Allan Hildesheim; John T Schiller; Mark Schiffman
Human papillomavirus infection and the primary and secondary prevention of cervical cancer.
Cancer 2008;113(7 Suppl):1980-93.
2008: John T Schiller; Xavier Castellsagué; Luisa L Villa; Allan Hildesheim
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
Vaccine 2008;26 Suppl 10():K53-61.
2008: Christopher B Buck; Naiqian Cheng; Cynthia D Thompson; Douglas Lowy; Alasdair C Steven; John T Schiller; Benes Trus
Arrangement of L2 within the papillomavirus capsid.
Journal of virology 2008;82(11):5190-7.
2008: Bryce Chackerian; Marisa R Durfee; John T Schiller
Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(9):5816-25.
2008: Patricia M Day; Ratish Gambhira; Richard B S Roden; Douglas Lowy; John T Schiller
Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies.
Journal of virology 2008;82(9):4638-46.
2008: Hannah H Alphs; Ratish Gambhira; Balasubramanyam Karanam; Jeffrey N Roberts; Subhashini Jagu; John T Schiller; Weiguang Zeng; David C Jackson; Richard B S Roden
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(15):5850-5.
2008: Troy J Kemp; Allan Hildesheim; Roni T Falk; John T Schiller; Douglas Lowy; Ana Cecilia Rodriguez; Ligia A Pinto
Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies.
Clinical and vaccine immunology : CVI 2008;15(1):60-4.
2007: Véronique Revaz; Rinaldo Zurbriggen; christian moser; John T Schiller; Françoise Ponci; Martine Bobst; Denise Nardelli-Haefliger
Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.
Antiviral research 2007;76(1):75-85.
2007: Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Ana Cecilia Rodriguez; Diane Solomon; M Concepcion Bratti; John T Schiller; Paula Gonzalez; Gary Dubin; Carolina Porras; Silvia E Jimenez; Douglas Lowy
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.
JAMA : the journal of the American Medical Association 2007;298(7):743-53.
2007: Alfonso J García-Piñeres; Allan Hildesheim; Lori Dodd; Troy J Kemp; Marcus Williams; Clayton D Harro; Douglas Lowy; John T Schiller; Ligia A Pinto
Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.
Clinical and vaccine immunology : CVI 2007;14(8):984-9.
2007: Patricia M Day; Cynthia D Thompson; Christopher B Buck; Yuk-Ying S Pang; Douglas Lowy; John T Schiller
Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.
Journal of virology 2007;81(16):8784-92.
2007: Jeffrey N Roberts; Christopher B Buck; Cynthia D Thompson; Rhonda Kines; Marcelino Bernardo; Peter L Choyke; Douglas Lowy; John T Schiller
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.
Nature medicine 2007;13(7):857-61.
2006: John T Schiller; Douglas Lowy
Prospects for cervical cancer prevention by human papillomavirus vaccination.
Cancer research 2006;66(21):10229-32.
2006: Ligia A Pinto; Raphael P Viscidi; Clayton D Harro; Troy J Kemp; Alfonso J García-Piñeres; Matthew Trivett; Franklin Demuth; Douglas Lowy; John T Schiller; Jay A Berzofsky; Allan Hildesheim
Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Virology 2006;353(2):451-62.
2006: John T Schiller; Denise Nardelli-Haefliger
Chapter 17: Second generation HPV vaccines to prevent cervical cancer.
Vaccine 2006;24 Suppl 3():S3/147-53.
2006: Farin Kamangar; You-Lin Qiao; John T Schiller; Sanford M Dawsey; Thomas R Fears; Xiu-Di Sun; Christian C Abnet; Ping Zhao; Philip R Taylor; Steven D Mark
Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in China.
International journal of cancer. Journal international du cancer 2006;119(3):579-84.
2006: Christopher B Buck; Cynthia D Thompson; Jeffrey N Roberts; Martin Müller; Douglas Lowy; John T Schiller
Carrageenan is a potent inhibitor of papillomavirus infection.
PLoS pathogens 2006;2(7):e69.
2006: Jiahua Qian; Yujun Dong; Yuk-Ying S Pang; Ramy Ibrahim; Jay A Berzofsky; John T Schiller; Samir N Khleif
Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
International journal of cancer. Journal international du cancer 2006;118(12):3022-9.
2006: Douglas Lowy; John T Schiller
Prophylactic human papillomavirus vaccines.
The Journal of clinical investigation 2006;116(5):1167-73.
2006: Christopher B Buck; Patricia M Day; Cynthia D Thompson; Jacek Lubkowski; Wuyuan Lu; Douglas Lowy; John T Schiller
Human alpha-defensins block papillomavirus infection.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(5):1516-21.
2006: Rebecca M Richards; Douglas Lowy; John T Schiller; Patricia M Day
Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(5):1522-7.
2006: Nadine Kämper; Patricia M Day; Thorsten Nowak; Hans-Christoph Selinka; Luise Florin; Jan Bolscher; Lydia Hilbig; John T Schiller; Martin Sapp
A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes.
Journal of virology 2006;80(2):759-68.
2005: Diana V Pastrana; Ratish Gambhira; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Timothy D Culp; Neil Christensen; Douglas Lowy; John T Schiller; Richard B S Roden
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.
Virology 2005;337(2):365-72.
2005: Denise Nardelli-Haefliger; Floriana Lurati; Daniel Wirthner; François Spertini; John T Schiller; Douglas Lowy; Françoise Ponci; Pierre De Grandi
Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine.
Vaccine 2005;23(28):3634-41.
2005: Ligia A Pinto; Philip E Castle; Richard B S Roden; Clayton D Harro; Douglas Lowy; John T Schiller; Dora Wallace; Marcus Williams; William Kopp; Ian H Frazer; Jay A Berzofsky; Allan Hildesheim
HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood.
Vaccine 2005;23(27):3555-64.
2005: Petra Lenz; Douglas Lowy; John T Schiller
Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells.
European journal of immunology 2005;35(5):1548-56.
2005: Christopher B Buck; Cynthia D Thompson; Yuk-Ying S Pang; Douglas Lowy; John T Schiller
Maturation of papillomavirus capsids.
Journal of virology 2005;79(5):2839-46.
2005: Christopher B Buck; Diana V Pastrana; Douglas Lowy; John T Schiller
Generation of HPV pseudovirions using transfection and their use in neutralization assays.
Methods in molecular medicine 2005;119():445-62.
2004: Patricia M Day; Carl Baker; Douglas Lowy; John T Schiller
Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(39):14252-7.
2004: Diana V Pastrana; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Philip E Castle; Peter C FitzGerald; Susanne Krüger-Kjaer; Douglas Lowy; John T Schiller
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.
Virology 2004;321(2):205-16.
2004: Bryce Chackerian; Lindsey Briglio; Paul S Albert; Douglas Lowy; John T Schiller
Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus.
Journal of virology 2004;78(8):4037-47.
2004: John T Schiller; Philip Davies
Delivering on the promise: HPV vaccines and cervical cancer.
Nature reviews. Microbiology 2004;2(4):343-7.
2004: Christopher B Buck; Diana V Pastrana; Douglas Lowy; John T Schiller
Efficient intracellular assembly of papillomaviral vectors.
Journal of virology 2004;78(2):751-7.
2003: Denise Nardelli-Haefliger; Daniel Wirthner; John T Schiller; Douglas Lowy; Allan Hildesheim; Françoise Ponci; Pierre De Grandi
Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.
Journal of the National Cancer Institute 2003;95(15):1128-37.
2003: Ligia A Pinto; Jessica Edwards; Philip E Castle; Clayton D Harro; Douglas Lowy; John T Schiller; Dora Wallace; William Kopp; Joseph W Adelsberger; Michael Baseler; Jay A Berzofsky; Allan Hildesheim
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
The Journal of infectious diseases 2003;188(2):327-38.
2003: Diane M Da Silva; John T Schiller; W Martin Kast
Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines.
Vaccine 2003;21(23):3219-27.
2003: Petra Lenz; Cynthia D Thompson; Patricia M Day; Silvia M Bacot; Douglas Lowy; John T Schiller
Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells.
Clinical immunology (Orlando, Fla.) 2003;106(3):231-7.
2003: Patricia M Day; Douglas Lowy; John T Schiller
Papillomaviruses infect cells via a clathrin-dependent pathway.
Virology 2003;307(1):1-11.
2002: May Wong; Joseph S Pagano; John T Schiller; Satvir S Tevethia; Nancy Raab-Traub; Jack Gruber
New associations of human papillomavirus, Simian virus 40, and Epstein-Barr virus with human cancer.
Journal of the National Cancer Institute 2002;94(24):1832-6.
2002: Bryce Chackerian; Petra Lenz; Douglas Lowy; John T Schiller
Determinants of autoantibody induction by conjugated papillomavirus virus-like particles.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(11):6120-6.
2001: Diane M Da Silva; Diana V Pastrana; John T Schiller; W Martin Kast
Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
Virology 2001;290(2):350-60.
2001: Richard B S Roden; Patricia M Day; B K Bronzo; Wil Yutzy; Y Yang; Douglas Lowy; John T Schiller
Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.
Journal of virology 2001;75(21):10493-7.
2001: Bryce Chackerian; Douglas Lowy; John T Schiller
Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies.
The Journal of clinical investigation 2001;108(3):415-23.
2001: John T Schiller; Douglas Lowy
Papillomavirus-like particle based vaccines: cervical cancer and beyond.
Expert opinion on biological therapy 2001;1(4):571-81.
2001: Petra Lenz; Patricia M Day; Yuk-Ying S Pang; Stephan Frye; P N Jensen; Douglas Lowy; John T Schiller
Papillomavirus-like particles induce acute activation of dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(9):5346-55.
2001: Diane M Da Silva; Markwin P Velders; JD Nieland; John T Schiller; Brian J Nickoloff; W Martin Kast
Physical interaction of human papillomavirus virus-like particles with immune cells.
International immunology 2001;13(5):633-41.
2001: M M Okun; Patricia M Day; HL Greenstone; frank booy; Douglas Lowy; John T Schiller; Richard B S Roden
L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation.
Journal of virology 2001;75(9):4332-42.
2001: Clayton D Harro; Yuk-Ying S Pang; Richard B S Roden; Allan Hildesheim; Z Wang; M J Reynolds; T C Mast; R Robinson; Brian Murphy; Ruth A Karron; J Dillner; John T Schiller; Douglas Lowy
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
Journal of the National Cancer Institute 2001;93(4):284-92.
2001: Susanne Krüger Kjaer; Bryce Chackerian; Adriaan J C van den Brule; Edith Ingerslev Svare; G Paull; J M Walbomers; John T Schiller; Johannes E Bock; Mark E Sherman; Douglas Lowy; C L Meijer
High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse).
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2001;10(2):101-6.
2001: Diana V Pastrana; William C Vass; Douglas Lowy; John T Schiller
NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.
Virology 2001;279(1):361-9.
2001: Véronique Revaz; Jalil Benyacoub; W M Kast; John T Schiller; Pierre De Grandi; Denise Nardelli-Haefliger
Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
Virology 2001;279(1):354-60.
2001: John T Schiller; Douglas Lowy
Papillomavirus-like particle vaccines.
Journal of the National Cancer Institute. Monographs 2001;(28):50-4.
2000: Richard B S Roden; Wil Yutzy; R Fallon; S Inglis; Douglas Lowy; John T Schiller
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
Virology 2000;270(2):254-7.
1999: Louise Wideroff; Mark Schiffman; P Haderer; A Armstrong; CE Greer; M Michele Manos; Robert D Burk; David R Scott; Mark E Sherman; John T Schiller; R N Hoover; R E Tarone; Reinhard Kirnbauer
Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions.
The Journal of infectious diseases 1999;180(5):1424-8.
1999: John T Schiller
Papillomavirus-like particle vaccines for cervical cancer.
Molecular medicine today 1999;5(5):209-15.
1999: JD Nieland; Diane M Da Silva; Markwin P Velders; Karin E de Visser; John T Schiller; Martin Müller; W Martin Kast
Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response.
Journal of cellular biochemistry 1999;73(2):145-52.
1999: Bryce Chackerian; Douglas Lowy; John T Schiller
Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(5):2373-8.
1999: Michael P Rudolf; JD Nieland; D M DaSilva; Markwin P Velders; Martin Müller; HL Greenstone; John T Schiller; W Martin Kast
Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles.
Biological chemistry 1999;380(3):335-40.
1999: Diane M Da Silva; Markwin P Velders; Michael P Rudolf; John T Schiller; W Martin Kast
Papillomavirus virus-like particles as anticancer vaccines.
Current opinion in molecular therapeutics 1999;1(1):82-8.
1999: Douglas Lowy; John T Schiller
Papillomaviruses: prophylactic vaccine prospects.
Biochimica et biophysica acta 1999;1423(1):M1-8.
1998: ML De Bruijn; HL Greenstone; H Vermeulen; Cornelis J M Melief; Douglas Lowy; John T Schiller; W Martin Kast
L1-specific protection from tumor challenge elicited by HPV16 virus-like particles.
Virology 1998;250(2):371-6.
1998: frank booy; Richard B S Roden; HL Greenstone; John T Schiller; Benes Trus
Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution.
Journal of molecular biology 1998;281(1):95-106.
1998: HL Greenstone; JD Nieland; Karin E de Visser; ML De Bruijn; Reinhard Kirnbauer; Richard B S Roden; Douglas Lowy; W Martin Kast; John T Schiller
Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(4):1800-5.
1998: Douglas Lowy; John T Schiller
Papillomaviruses and cervical cancer: pathogenesis and vaccine development.
Journal of the National Cancer Institute. Monographs 1998;(23):27-30.
1998: Patricia M Day; Richard B S Roden; Douglas Lowy; John T Schiller
The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains.
Journal of virology 1998;72(1):142-50.
1997: Richard B S Roden; Douglas Lowy; John T Schiller
Papillomavirus is resistant to desiccation.
The Journal of infectious diseases 1997;176(4):1076-9.
1997: Edith Ingerslev Svare; Susanne Krüger Kjaer; Bernadete Nonnenmacher; AM Worm; H Moi; R B Christensen; Adriaan J C van den Brule; JM Walboomers; Chris J L M Meijer; NL Hubbert; Douglas Lowy; John T Schiller
Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women.
The Journal of infectious diseases 1997;176(4):876-83.
1997: Denise Nardelli-Haefliger; Richard B S Roden; Jalil Benyacoub; Roland Sahli; JP Kraehenbuhl; John T Schiller; P Lachat; Alexandra Potts; Pierre De Grandi
Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.
Infection and immunity 1997;65(8):3328-36.
1997: Richard B S Roden; A Armstrong; P Haderer; Neil Christensen; NL Hubbert; Douglas Lowy; John T Schiller; Reinhard Kirnbauer
Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.
Journal of virology 1997;71(8):6247-52.
1997: Howard D Strickler; Allan Hildesheim; Raphael P Viscidi; Keerti V Shah; B Goebel; James Drummond; D Waters; Yi Sun; NL Hubbert; Sholom Wacholder; L A Brinton; C L Han; P C Nasca; R McClimens; K Turk; V Devairakkam; S Leitman; C Martin; John T Schiller
Interlaboratory agreement among results of human papillomavirus type 16 enzyme-linked immunosorbent assays.
Journal of clinical microbiology 1997;35(7):1751-6.
1997: Benes Trus; Richard B S Roden; HL Greenstone; M Vrhel; John T Schiller; frank booy
Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution.
Nature structural biology 1997;4(5):413-20.
1997: Howard D Strickler; Mark Schiffman; C Eklund; Andrew G. Glass; David R Scott; Mark E Sherman; Sholom Wacholder; Robert J Kurman; M Michele Manos; John T Schiller; Joakim Dillner
Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1997;6(3):183-8.
1996: B Nonnenmacher; S Kruger Kjaer; Edith Ingerslev Svare; J D Scott; N L Hubbert; Adriaan J C van den Brule; Reinhard Kirnbauer; JM Walboomers; Douglas Lowy; John T Schiller
Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations.
International journal of cancer. Journal international du cancer 1996;68(6):704-9.
1996: John T Schiller; Douglas Lowy
Papillomavirus-like particles and HPV vaccine development.
Seminars in cancer biology 1996;7(6):373-82.
1996: Z Wang; Bengt Göran Hansson; Ola Forslund; L Dillner; M Sapp; John T Schiller; B Bjerre; Joakim Dillner
Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA.
Journal of clinical microbiology 1996;34(12):3056-62.
1996: MA Steller; Z Zou; John T Schiller; R Baserga
Transformation by human papillomavirus 16 E6 and E7: role of the insulin-like growth factor 1 receptor.
Cancer research 1996;56(21):5087-91.
1996: C Han; G Qiao; N L Hubbert; L Li; C Sun; Y Wang; M Yan; D Xu; Y Li; Douglas Lowy; John T Schiller
Serologic association between human papillomavirus type 16 infection and esophageal cancer in Shaanxi Province, China.
Journal of the National Cancer Institute 1996;88(20):1467-71.
1996: Richard B S Roden; HL Greenstone; Reinhard Kirnbauer; frank booy; J Jessie; Douglas Lowy; John T Schiller
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.
Journal of virology 1996;70(9):5875-83.
1996: Joakim Dillner; I Kallings; C Brihmer; B Sikström; P Koskela; Matti Lehtinen; John T Schiller; M Sapp; Per-Anders Mårdh
Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior.
The Journal of infectious diseases 1996;173(6):1394-8.
1996: Richard B S Roden; N L Hubbert; Reinhard Kirnbauer; Neil Christensen; Douglas Lowy; John T Schiller
Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition.
Journal of virology 1996;70(5):3298-301.
1996: Reinhard Kirnbauer; L M Chandrachud; BW O'Neil; E R Wagner; G Joan Grindlay; A Armstrong; G M McGarvie; John T Schiller; Douglas Lowy; M Saveria Campo
Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.
Virology 1996;219(1):37-44.
1996: MA Steller; John T Schiller
Human papillomavirus immunology and vaccine prospects.
Journal of the National Cancer Institute. Monographs 1996;(21):145-8.
1996: Douglas Lowy; John T Schiller
Human papillomavirus biology.
Journal of the National Cancer Institute. Monographs 1996;(21):141-3.
1996: John T Schiller; M M Okun
Papillomavirus vaccines: current status and future prospects.
Advances in dermatology 1996;11():355-80; discussion 381.
1995: G Cheng; Joseph P Icenogle; Reinhard Kirnbauer; N L Hubbert; Michael St. Louis; C Han; Edith Ingerslev Svare; Susanne Krüger Kjaer; Douglas Lowy; John T Schiller
Divergent human papillomavirus type 16 variants are serologically cross-reactive.
The Journal of infectious diseases 1995;172(6):1584-7.
1995: Richard B S Roden; N L Hubbert; Reinhard Kirnbauer; Françoise Breitburd; Douglas Lowy; John T Schiller
Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor.
Journal of virology 1995;69(8):5147-51.
1995: B Nonnenmacher; N L Hubbert; Reinhard Kirnbauer; Keerti V Shah; N Muñoz; F X Bosch; S de Sanjosé; Raphael P Viscidi; Douglas Lowy; John T Schiller
Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain.
The Journal of infectious diseases 1995;172(1):19-24.
1995: Françoise Breitburd; Reinhard Kirnbauer; N L Hubbert; B Nonnenmacher; C Trin-Dinh-Desmarquet; Gérard Orth; John T Schiller; Douglas Lowy
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.
Journal of virology 1995;69(6):3959-63.
1995: P Heino; C Eklund; V Fredriksson-Shanazarian; S Goldman; John T Schiller; Joakim Dillner
Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma.
Journal of the National Cancer Institute 1995;87(6):437-40.
1995: A Wikström; G J van Doornum; W G Quint; John T Schiller; Joakim Dillner
Identification of human papillomavirus seroconversions.
The Journal of general virology 1995;76 ( Pt 3)():529-39.
1995: Joakim Dillner; Fredrik Wiklund; P Lenner; C Eklund; V Frederiksson-Shanazarian; John T Schiller; M Hibma; G Hallmans; U Stendahl
Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer.
International journal of cancer. Journal international du cancer 1995;60(3):377-82.
1994: R M Melillo; K Helin; Douglas Lowy; John T Schiller
Positive and negative regulation of cell proliferation by E2F-1: influence of protein level and human papillomavirus oncoproteins.
Molecular and cellular biology 1994;14(12):8241-9.
1994: Richard B S Roden; Reinhard Kirnbauer; A B Jenson; Douglas Lowy; John T Schiller
Interaction of papillomaviruses with the cell surface.
Journal of virology 1994;68(11):7260-6.
1994: Richard B S Roden; Eva M Weissinger; DW Henderson; frank booy; Reinhard Kirnbauer; J Frederic Mushinski; Douglas Lowy; John T Schiller
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.
Journal of virology 1994;68(11):7570-4.
1994: Reinhard Kirnbauer; N L Hubbert; Cosette M Wheeler; Thomas M Becker; Douglas Lowy; John T Schiller
A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.
Journal of the National Cancer Institute 1994;86(7):494-9.
1994: Douglas Lowy; Reinhard Kirnbauer; John T Schiller
Genital human papillomavirus infection.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(7):2436-40.
1993: Reinhard Kirnbauer; J Taub; HL Greenstone; Richard B S Roden; M Dürst; L Gissmann; Douglas Lowy; John T Schiller
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.
Journal of virology 1993;67(12):6929-36.
1993: B D Cohen; Douglas Lowy; John T Schiller
The conserved C-terminal domain of the bovine papillomavirus E5 oncoprotein can associate with an alpha-adaptin-like molecule: a possible link between growth factor receptors and viral transformation.
Molecular and cellular biology 1993;13(10):6462-8.
1993: B D Cohen; D J Goldstein; L Rutledge; William C Vass; Douglas Lowy; Richard Schlegel; John T Schiller
Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain.
Journal of virology 1993;67(9):5303-11.
1993: Douglas Lowy; S A Sedman; B D Cohen; John T Schiller
Human papillomaviruses and cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;128():351-2.
1992: Reinhard Kirnbauer; frank booy; Naiqian Cheng; Douglas Lowy; John T Schiller
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(24):12180-4.
1992: N L Hubbert; S A Sedman; John T Schiller
Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes.
Journal of virology 1992;66(10):6237-41.
1992: S A Sedman; N L Hubbert; William C Vass; Douglas Lowy; John T Schiller
Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated trans-activation or transforming activity.
Journal of virology 1992;66(7):4201-8.
1991: S A Sedman; M S Barbosa; William C Vass; N L Hubbert; J A Haas; Douglas Lowy; John T Schiller
The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture.
Journal of virology 1991;65(9):4860-6.
1991: M S Barbosa; William C Vass; Douglas Lowy; John T Schiller
In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential.
Journal of virology 1991;65(1):292-8.
1990: M S Barbosa; C Edmonds; C Fisher; John T Schiller; Douglas Lowy; Karen H Vousden
The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation.
The EMBO journal 1990;9(1):153-60.
1989: P Hawley-Nelson; Karen H Vousden; N L Hubbert; Douglas Lowy; John T Schiller
HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes.
The EMBO journal 1989;8(12):3905-10.
1989: P Martin; William C Vass; John T Schiller; Douglas Lowy; T J Velu
The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors.
Cell 1989;59(1):21-32.
1989: Paul F Lambert; N L Hubbert; Peter M Howley; John T Schiller
Genetic assignment of multiple E2 gene products in bovine papillomavirus-transformed cells.
Journal of virology 1989;63(7):3151-4.
1989: Christa Cerni; B Binétruy; John T Schiller; Douglas Lowy; G Meneguzzi; François Cuzin
Successive steps in the process of immortalization identified by transfer of separate bovine papillomavirus genes into rat fibroblasts.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(9):3266-70.
1989: Karen H Vousden; E J Androphy; John T Schiller; Douglas Lowy
Mutational analysis of bovine papillomavirus E6 gene.
Journal of virology 1989;63(5):2340-2.
1989: John T Schiller; E Kleiner; E J Androphy; Douglas Lowy; H Pfister
Identification of bovine papillomavirus E1 mutants with increased transforming and transcriptional activity.
Journal of virology 1989;63(4):1775-82.
1989: M S Barbosa; Douglas Lowy; John T Schiller
Papillomavirus polypeptides E6 and E7 are zinc-binding proteins.
Journal of virology 1989;63(3):1404-7.
1988: N L Hubbert; John T Schiller; Douglas Lowy; E J Androphy
Bovine papilloma virus-transformed cells contain multiple E2 proteins.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(16):5864-8.
1988: P Hawley-Nelson; E J Androphy; Douglas Lowy; John T Schiller
The specific DNA recognition sequence of the bovine papillomavirus E2 protein is an E2-dependent enhancer.
The EMBO journal 1988;7(2):525-31.
1987: E J Androphy; N L Hubbert; John T Schiller; Douglas Lowy
Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines.
The EMBO journal 1987;6(4):989-92.
1985: Douglas Lowy; John T Schiller
Papillomaviruses.
Clinics in dermatology 1985;3(4):1-7.